Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
Madhi, Shabir A, Moodley, Dhayendre, Hanley, Sherika, Archary, Moherndran, Hoosain, Zaheer, Lalloo, Umesh, Louw, Cheryl, Fairlie, Lee, Fouche, Leon Frederik, Masilela, Mduduzi S L, Singh, Nishanta, Grobbelaar, Coert, Ahmed, Khatija, Benadé, Gabriella, Bhikha, Sutika, Bhorat, As'ad Ebrahim, Bhorat, Qasim, Joseph, Natasha, Dheda, Keertan, Esmail, Aliasgar, Foulkes, Sharne, Goga, Ameena, Oommen Jose, Aylin, Kruger, Gertruida, Kalonji, Dishiki J, Lalloo, Natasha, Lombaard, Johan J, Lombard Koen, Anthonet, Kany Luabeya, Angelique, Mngqibisa, Rosie, Petrick, Friedrich G, Pitsi, Annah, Tameris, Michele, Thombrayil, Asha, Vollgraaff, Pieter-Louis, Cloney-Clark, Shane, Zhu, Mingzhu, Bennett, Chijioke, Albert, Gary, Faust, Emmanuel, Plested, Joyce S, Fries, Lou, Robertson, Andreana, Neal, Susan, Cho, Iksung, Glenn, Greg M, Shinde, Vivek
Published in The lancet HIV (01.05.2022)
Published in The lancet HIV (01.05.2022)
Get more information
Journal Article